Pharvaris N.V. (PHVS) Stock Price, Quote & News

Company Profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 tria...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 712036410

Website: pharvaris.com

Address:

Grafenauweg 8, Zug, Switzerland

VolumeDiver Feb. 18 at 10:18 AM

$PHVS Oncology biotech where clinical readouts define valuation.

0 · Reply

Smellmahass Feb. 10 at 2:23 PM

$PHVS They releasing mew data on Feb 27?

0 · Reply

Saffier1988 Feb. 6 at 8:42 PM

$BCRX $PHVS sure Pharvaris with no revenue more worth than BCRX

0 · Reply

MilaGoldframe01 Feb. 6 at 9:23 AM

$KALV Info for the "no risk" longs on this board. Yes, the balance sheet and market adaption here look quite nice. But apart from $PHVS the upcoming $NTLA P3 results expected mid year pose a pretty big threat to any HAE comp out there. Data presented on November 8, 2025, showed that 31 of 32 patients (97%) were attack-free and long-term prophylaxis (LTP)-free at data cutoff. If they reproduce these results in P3 and Gene editing is accepted by the patient population, the on demand market will shrink significantly. I think thats reason for the giant short interest.

0 · Reply

CreditCurve Feb. 4 at 1:39 PM

$PHVS is a clinical-stage biotech developing photodynamic therapies for cancer; its technology is novel but unproven at scale, representing a high-risk, high-reward investment.

0 · Reply

SuperGreenToday Jan. 23 at 4:53 AM

$PHVS

0 · Reply

Sambong Jan. 22 at 5:59 AM

$PHVS volume pick up right shoulder formation.. over 30 sends it. watch for head fake

0 · Reply

OfficialStocktwitsUser Jan. 20 at 7:10 PM

$PHVS RSI: 51.49, MACD: 0.1420 Vol: 0.80, MA20: 25.79, MA50: 25.21 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

JFais Jan. 12 at 1:04 PM

$BCRX $601M in Orladeyo revenues for 2026 and still growing +37% yoy (impressive for a subpar drug!) Clearly shows the demand is there & + building the oral market for $KALV $PHVS

3 · Reply

monoksop Jan. 8 at 9:10 AM

$BCRX What does everyone think about $PHVS? Data looks very very good, both acute and prophylactic treatments in one compound. 84% attack reduction rate for an oral is pretty sensational.

2 · Reply

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Jan 12, 2026, 6:50 AM EST - 6 weeks ago

Pharvaris Outlines 2026 Strategic Priorities

Dec 3, 2025, 5:43 PM EST - 2 months ago

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

Dec 3, 2025, 10:09 AM EST - 2 months ago

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Dec 3, 2025, 6:50 AM EST - 2 months ago

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

Nov 23, 2025, 5:36 AM EST - 3 months ago

Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating

Nov 12, 2025, 6:50 AM EST - 3 months ago

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 6:50 AM EST - 3 months ago

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

Oct 23, 2025, 6:50 AM EDT - 4 months ago

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

Sep 10, 2025, 1:07 PM EDT - 5 months ago

Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 5, 2025, 1:04 AM EDT - 6 months ago

Pharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 4, 2025, 5:25 AM EDT - 6 months ago

Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 12, 2025, 4:05 PM EDT - 6 months ago

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 23, 2025, 3:15 PM EDT - 7 months ago

Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations

Jul 22, 2025, 9:22 PM EDT - 7 months ago

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Jul 22, 2025, 4:05 PM EDT - 7 months ago

Pharvaris Announces Proposed Public Offering of Ordinary Shares

Jul 18, 2025, 4:41 AM EDT - 7 months ago

Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success

Jul 10, 2025, 6:50 AM EDT - 8 months ago

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Jun 27, 2025, 6:50 AM EDT - 8 months ago

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

Jun 16, 2025, 6:50 AM EDT - 9 months ago

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress

Jun 10, 2025, 6:50 AM EDT - 9 months ago

Pharvaris Announces Annual Meeting of Shareholders

Jun 2, 2025, 6:50 AM EDT - 9 months ago

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema

May 19, 2025, 6:50 AM EDT - 10 months ago

Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses

May 13, 2025, 4:05 PM EDT - 10 months ago

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 6:50 AM EDT - 10 months ago

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4

Apr 7, 2025, 6:58 AM EDT - 11 months ago

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Apr 1, 2025, 6:50 AM EDT - 11 months ago

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Mar 3, 2025, 6:50 AM EST - 1 year ago

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Mar 3, 2025, 6:48 AM EST - 1 year ago

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Jan 13, 2025, 6:50 AM EST - 1 year ago

Pharvaris Outlines 2025 Strategic Priorities

Nov 13, 2024, 4:10 PM EST - 1 year ago

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Nov 12, 2024, 6:50 AM EST - 1 year ago

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Oct 16, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Oct 15, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Host Virtual Investor Event on October 23, 2024

Oct 3, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Sep 5, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Sep 5, 2024, 6:49 AM EDT - 1 year ago

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Sep 5, 2024, 6:48 AM EDT - 1 year ago

Pharvaris Presents Data at the Bradykinin Symposium 2024

Aug 28, 2024, 6:50 AM EDT - 1 year ago

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Aug 14, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 4, 2024, 6:50 AM EDT - 1 year ago

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

May 13, 2024, 6:50 AM EDT - 1 year ago

Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

May 8, 2024, 4:10 PM EDT - 1 year ago

Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 10, 2024, 4:10 PM EDT - 2 years ago

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Apr 10, 2024, 4:08 PM EDT - 2 years ago

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Apr 4, 2024, 6:50 AM EDT - 2 years ago

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Mar 18, 2024, 6:50 AM EDT - 2 years ago

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

Mar 6, 2024, 6:50 AM EST - 2 years ago

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Mar 5, 2024, 6:50 AM EST - 2 years ago

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Feb 22, 2024, 6:50 AM EST - 2 years ago

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

VolumeDiver Feb. 18 at 10:18 AM

$PHVS Oncology biotech where clinical readouts define valuation.

0 · Reply

Smellmahass Feb. 10 at 2:23 PM

$PHVS They releasing mew data on Feb 27?

0 · Reply

Saffier1988 Feb. 6 at 8:42 PM

$BCRX $PHVS sure Pharvaris with no revenue more worth than BCRX

0 · Reply

MilaGoldframe01 Feb. 6 at 9:23 AM

0 · Reply

CreditCurve Feb. 4 at 1:39 PM

$PHVS is a clinical-stage biotech developing photodynamic therapies for cancer; its technology is novel but unproven at scale, representing a high-risk, high-reward investment.

0 · Reply

SuperGreenToday Jan. 23 at 4:53 AM

$PHVS

0 · Reply

Sambong Jan. 22 at 5:59 AM

$PHVS volume pick up right shoulder formation.. over 30 sends it. watch for head fake

0 · Reply

OfficialStocktwitsUser Jan. 20 at 7:10 PM

0 · Reply

JFais Jan. 12 at 1:04 PM

$BCRX $601M in Orladeyo revenues for 2026 and still growing +37% yoy (impressive for a subpar drug!) Clearly shows the demand is there & + building the oral market for $KALV $PHVS

3 · Reply

monoksop Jan. 8 at 9:10 AM

$BCRX What does everyone think about $PHVS? Data looks very very good, both acute and prophylactic treatments in one compound. 84% attack reduction rate for an oral is pretty sensational.

2 · Reply

JuggernautRaider Jan. 4 at 4:14 PM

$KALV I’m surprised Kalvista hasn’t gotten more buying rumors. Are they planning to go it alone in HAE like $PHAR ans $PHVS ? @Night_Owl_Biotech : I think each of these is a likely buyout target in 2026, although $NUVB is the top of my list 🏦 Any thoughts? Don’t be shy, @BioCapitalist99 or @Biotech_Beast ! I’ll get my BiotechBonesaw handle back eventually. Maybe I’ll argue with myself on here 😂

2 · Reply

WallStreetBuyDip Jan. 1 at 9:41 PM

Comparing trending tickers $PHVS vs $WYY: PHVS is up 5.71% to $27.75 on a volume of 427.0K shares, which is significantly above its average of 158.0K shares. In contrast, WYY is down 2.54% to $5.37 with a trading volume of 64.4K shares, slightly below its average volume of 72.0K shares. PHVS is showing stronger positive momentum with a substantial increase in trading volume, while WYY's decrease in price isn't supported by increased trading activity.

0 · Reply

WallStreetBuyDip Jan. 1 at 9:22 PM

Comparing trending tickers $CCJ vs $PHVS: CCJ is currently priced at $91.49, showing a marginal increase of 0.13%, with trading volume at 1.6 million shares, significantly below its average of 4.7 million. In contrast, PHVS has jumped 5.71% to $27.75, with a trading volume of 427,000 shares, which is nearly 3 times its average volume of 158,000. While PHVS is experiencing a notable price surge on elevated volume, CCJ's slight price change comes amidst lower than typical trading activity.

0 · Reply

BillionerOfKing Jan. 1 at 7:25 PM

$PHVS Current Stock Price: $27.77 Contracts to trade: $30 PHVS Jan 16 2026 Call Entry: $1.70 Exit: $2.98 ROI: 76% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SmartBetaV3 Dec. 26 at 4:01 PM

$PHVS Capital is flowing toward execution strength rather than speculative optionality. Improving execution cadence across quarters would alter sentiment materially. Evidence of repeatability is likely to change market tone. Without validation, volatility will remain persistent.

0 · Reply

TheHiddenMass Dec. 24 at 12:06 PM

$PHVS Current positioning will be tested as timelines compress uncertainty rather than extend speculation. Delays or dilution could materially reshape the risk profile.

0 · Reply

Arcides Dec. 10 at 5:40 PM

$PHVS total disgrace after big pop 6 days ago.

0 · Reply

Quantumup Dec. 4 at 6:35 PM

Morgan Stanley⬆️ $PHVS' PT to $41 from $37 and reiterated at Overweight $KALV Oppenheimer⬆️to $50 from $44 and reit'd at Outperform Guggenheim⬆️to $39 from $32, +⬆️its🌐peak sales ests for deucrictibant to $1.65B from $1.4B Here's what the Analysts said in their notes: https://x.com/Quantumup1/status/1996647560816087150?s=20

0 · Reply

ZacksResearch Dec. 4 at 6:11 PM

PHVS ripping higher — is this the momentum shift bulls wanted? Deucrictibant hit its late-stage marks with rapid symptom relief in RAPIDe-3, and the win is pushing $PHVS toward a planned 2026 regulatory filing. Full breakdown here 👉 https://www.zacks.com/stock/news/2799891/pharvaris-stock-gains-on-hae-drug-meeting-late-stage-study-goals?cid=sm-stocktwits-2-2799891-teaser-23504&ADID=SYND_STOCKTWITS_TWEET_2_2799891_TEASER_23504

0 · Reply

JarvisFlow Dec. 4 at 6:10 PM

Oppenheimer has updated their rating for Pharvaris ( $PHVS ) to Outperform with a price target of 50.

0 · Reply

ZacksResearch Dec. 4 at 5:11 PM

$PHVS skyrockets 22% on positive phase III results for HAE drug! 🚀 🎯 Deucrictibant achieved its primary endpoint and all secondary endpoints in RAPIDe-3 study, offering faster relief than placebo. 💊 83% of attacks managed with one dose; 93% without backup treatment. Find out what this means for Pharvaris and its competition with $KALV 👉 https://www.zacks.com/stock/news/2799891/pharvaris-stock-gains-on-hae-drug-meeting-late-stage-study-goals?cid=sm-stocktwits-2-2799891-body-23505&ADID=SYND_STOCKTWITS_TWEET_2_2799891_BODY_23505

0 · Reply

TwongStocks Dec. 4 at 3:29 PM

$PHVS They currently have 3 USPTO trademark applications for the following names: • HAEBRII, application filed June 30, 2025 • ATASFRII, application filed Mar 26, 2025 • BRADIFRII, application filed Mar 26, 2025 Unless they process additional applications, I assume one of these names will be the marketing name for deucrictibant.

0 · Reply

Market Cap	1.47B
Revenue (ttm)	0.00
Net Income (ttm)	-145.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	61,500
Avg Vol	204,576
Day's Range	N/A - N/A
Shares Out	52.29M
Stochastic %K	77%
Beta	-2.79
Analysts	Strong Sell
Price Target	$44.50